Head to Toe Healthcare Center Expands Shockwave Therapy Services
TUCSON, AZ / ACCESS Newswire / June 17, 2025 / Head to Toe Healthcare, PLC, led by founder and medical director Dr. Alan Shih, has announced the expansion of its shockwave therapy services, bringing globally informed, non-invasive treatment options to more patients in Southern Arizona.
This milestone comes on the heels of Dr. Shih's recent participation in the 25th World Congress of the International Society for Medical Shockwave Treatment, held in South Korea. There, he engaged with leading practitioners and researchers to deepen his understanding of the fast-evolving field of shockwave therapy and its growing potential across multiple areas of medicine.
"Attending the World Congress was a reminder that the U.S. still has a lot of catching up to do in this space," said Dr. Shih. "In Europe and Asia, shockwave therapy is a standard option for many conditions. I'm committed to bringing those advancements here to Tucson, to evolve faster than the average and offer my patients the best care available."
Shockwave therapy, originally developed as a derivative of lithotripsy (a treatment for kidney stones), uses high-energy sound waves to stimulate healing in musculoskeletal tissues. The treatment is completely non-invasive (the skin is not pierced) and has been shown to decrease scar tissue, improve microcirculation, and accelerate recovery times, often without the need for surgery.
At Head to Toe Healthcare, Dr. Shih primarily utilizes shockwave therapy to treat chronic conditions such as Achilles tendonitis and plantar fasciitis, but he is also pioneering its use in other challenging cases, including neuropathy, an area of his clinical expertise.
One of the most appealing aspects of the treatment is its efficacy. When Dr. Shih recommends that his patients engage in the shockwave procedure, it takes roughly 10-15 minutes, once a week, over a span of four weeks in many cases. "Many report feeling significant relief even after the first treatment. Some have dealt with pain for years, and now they're walking out of here feeling better than they thought possible."
According to a recent article by the Journal of the American Medical Association, it usually takes around 17 years for evidence to change practice within the medical field delay Dr. Shih finds unacceptable. "If we wait that long, we're doing our patients a disservice," he said. "My goal is to constantly evaluate what's working globally and bring it into practice today, not tomorrow."
With this latest expansion, Dr. Shih and his team are actively pursuing additional applications of shockwave therapy and are focused on refining treatment protocols for neuropathy and other difficult-to-treat conditions. The healthcare center is also gathering ongoing patient feedback to better measure long-term outcomes and push the frontier of what's possible with the therapy.
Dr. Shih's dedication to lifelong learning and innovation has earned him praise throughout Tucson's medical community, and his patients are feeling the results.
"It's been astonishing to see our patients getting better after treating them with shockwave therapy," says Dr. Shih. "My patients are getting better at a much faster rate without the need for surgery. Some of the people I have treated have been suffering for years, and the use of shockwave has allowed them to feel much better, something they didn't think was possible."
"It's been astonishing to see our patients getting better after treating them with shockwave therapy," said Dr. Shih. "We're seeing improvements that would typically take months, if not require surgery, happen within weeks. That's the kind of impact every doctor dreams of making."
As Head to Toe Healthcare continues to grow its offerings, Dr. Shih remains focused on one mission: providing effective, evidence-based, and future-forward care for every patient who walks through the door.
Media Contact : Dr Alan ShihEmail : hang10@headtotoehealthcare.orghttps://headtotoehealthcare.org/(520) 545-0202
SOURCE: Dr Alan Shih
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
4 hours ago
- Miami Herald
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation. Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects. "These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential," said Erez Aminov, Chairman and CEO of MIRA. "We believe the drug's ability to match morphine's pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It's another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain." Study Overview and Key Findings Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat's paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume. Key findings: Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline analgesic effect was equivalent to morphine, the standard opioid comparator in the sedation or inflammatory swelling was observed with Mira-55 treatment. Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound's long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development. These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55's selective pharmacological profile. "Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today's standards." Strategic Fit Within MIRA's Pain Portfolio Mira-55 complements Ketamir-2, MIRA's clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain. "With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated," added Aminov. "We're advancing each asset methodically, and we're energized by the momentum we've built across the pipeline." Corporate Update on SKNY Merger MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction. "We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation," said Aminov. "This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth." Next Steps MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones. About MIRA Pharmaceuticals, Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking StatementsThis press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals
Miami Herald
a day ago
- Miami Herald
New Horizon Medical Solutions Adds AmchoPlast(TM) to its Industry-Best Product Portfolio
Next‑Gen Amnio-Chorionic Membrane for Enhanced Wound Care is Latest Offering in a Slew of New Products Focused on Increasing Patient Care LAS VEGAS, NV / ACCESS Newswire / July 1, 2025 / New Horizon Medical Solutions, a leader in advanced biologics and wound care innovation, today announced the launch and addition of AmchoPlast™ to its product portfolio. AmchoPlast is a premium amniotic‑chorionic membrane (amnion - chorion with intermediate layer) product designed to elevate outcomes across surgical and chronic wound indications. "AmchoPlast strengthens our pipeline of compliant, performance-driven biologics that align with modern wound care protocols," said Will Hall, CEO, New Horizon Medical Solutions. "This launch reflects our commitment to regenerative medicine, practice optimization, and elevating standards of care." Delivering superior benefits and practice optimization Engineered with amiotic-chorionic tissue, AmchoPlast serves as a natural biologic scaffold and barrier, supporting advanced wound care and non-immunogenic, the membrane is safe for a diverse patient population and a wide range of wound construction provides enhanced handling properties and slower degradation compared to single or bi-layer membranes Designed for clinical workflow and reimbursement ease Supplied in a sterile, ready-to-use format, AmchoPlast cuts procedural prep time and minimizes infection at room temperature, it supports versatile storage for hospitals, clinics, or mobile easy-to-handle, and available in multiple sizes, it facilitates precise application and reduces product wastage. "The addition of AmchoPlast cements our portfolio as the most complete in the biologics space," said D. Christopher Keil, SVP, strategy & corporate development. "We now offer providers and partners the broadest range of choices when selecting regenerative solutions from New Horizon." About AmchoPlast™ AmchoPlast, from Cellution Biologics, combines the power of amniotic and chorionic tissues with intermediate layer in a tri-layered construct. Intended to act as a barrier and provide protective coverage from the surrounding environment for acute and chronic wounds such as partial and full thickness wounds, pressure sores/ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (e.g., donor site/grafts, post-laser surgery, post-Mohs surgery, podiatric wounds, wound dehiscence), trauma wounds (e.g., abrasions, lacerations, partial thickness burns, skin tears), and draining wounds. For more information on the product, visit or contact New Horizon Medical Solutions directly at 702-960-2913. About New Horizon Medical Solutions New Horizon Medical Solutions is at the forefront of biologic innovation and practice optimization. The company develops regenerative tissue products supported by reimbursement expertise and operational efficiency, empowering providers to improve patient outcomes while maintaining compliance. --Media Contact Julian Rogers, Director of Corporate MarketingNew Horizon Medical SOURCE: New Horizon Medical Solutions
Associated Press
2 days ago
- Associated Press
Imagene AI Hits $45M in Total Funding After Completing $23M Series B Led by Larry Ellison
Imagene AI delivers a living intelligence engine for adaptive, insight-driven precision medicine. MIAMI, FL / ACCESS Newswire / July 1, 2025 / Imagene AI, a pioneer in multi‑modal foundation models for precision medicine, today announced the successful close of a $23 million Series B financing round led by Oracle Chairman and CTO Larry Ellison. This latest infusion brings Imagene AI's total capital raised to $45 million under terms that reflect the company's accelerating momentum and expanding strategic footprint. The round also included participation from existing investor Aguras Pathology Investments. 'We are honored to have the continued support of one of the world's foremost technology visionaries,' said Dean Bitan, CEO and Co‑founder of Imagene AI. 'We're developing the core intelligence that allows precision medicine to function as an adaptive, insight-driven system - from real-time trial design to rapid patient identification and more informed clinical decisions. Our goal is to make every trial more responsive, every insight more actionable, and every patient journey more personalized.' 'Imagene AI's ability to unite imaging, omics, and clinical data in a single foundation model is exactly the kind of breakthrough we believe will drive the next generation of drugs and diagnostics,' said Larry Ellison, Oracle Chairman and CTO. 'Their approach opens the door to a more adaptive, biologically fluent era of precision medicine.' Powering Living Precision Medicine Through Adaptive Intelligence At the core of Imagene AI is a dynamic intelligence infrastructure, an orchestration layer that continuously evolves with every stream of biological and clinical data. Histopathology, molecular profiles, and clinical context are routed in real-time through our proprietary foundation models, large language models, and biology-tuned analysis continuous loop ensures insights remain current and biologically grounded, empowering clinicians and researchers with personalized, up-to-date guidance at every stage of the trial. This momentum builds on a series of important milestones. Imagene AI's state-of-the-art digital pathology foundation model, trained on more than 1.5 million biopsy images, has demonstrated benchmark performance in key research tasks, particularly when working with limited data, a challenge common in real-world scenarios. The company launched the OI Suite platform to a broader community of users, including non-AI experts, delivering capabilities for biomarker discovery, indication expansion, and patient identification across multiple therapeutic areas. Additionally, Imagene AI is expanding strategic collaborations, such as its partnership with Tempus, to bring rapid predictive assays to more clinicians and patients, guiding treatment decisions with greater precision. Contact InformationAvital Rabani VP of Marketing SOURCE: Imagene press release
